American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Original Article
Neuropsychopharmacology (1998) 18 364-369.10.1038/sj.npp.1395147

Effect of Carbamazepine on the Single Oral Dose Pharmacokinetics of Alprazolam

Hanako Furukori1 MD, Koichi Otani3 MD, Ph.D, Norio Yasui1 MD, Ph.D, Tsuyoshi Kondo1 MD, Ph.D, Sunao Kaneko1 MD, Ph.D, Ritsuko Shimoyama2 BS, Tadashi Ohkubo2 Ph.D, Takako Nagasaki2 BS and Kazunobu Sugawara2 Ph.D
1Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki, Japan
2Pharmacy, Hirosaki University Hospital, Hirosaki, Japan
3Department of Neuropsychiatry, Yamagata University School of Medicine, Yamagata, Japan

Correspondence: Dr Tsuyoshi Kondo, Department of Neuropsychiatry, Hirosaki University Hospital, Hon-cho 53, Hirosaki 036, Japan

ABSTRACT

The effect of carbamazepine, an inducer of cytochrome P450 (CYP) 3A4, on the single oral dose pharmacokinetics of alprazolam was examined in a double-blind, randomized crossover study with two phases. Seven healthy male subjects took carbamazepine 300 mg/day or matched placebo orally for 10 days, and on the 8th day they took a single oral 0.8 mg dose of alprazolam. Blood samples were taken and psychomotor function was assessed by the Digit Symbol Substitution Test, Visual Analog Scale, and UKU Side Effect Rating Scale up to 48 h after alprazolam dosing. Carbamazepine significantly (p < .01 to .001) decreased the plasma alprazolam concentrations during the elimination phase. Carbamazepine significantly (p < .001) increased the apparent oral clearance (0.90 ± 0.21 vs. 2.13 ± 0.54 ml/min/kg) and shortened the elimination half-life (17.1 ± 4.9 vs. 7.7 ± 1.7 h), with no significant effect on the peak plasma concentration (11.7 ± 1.5 vs. 13.0 ± 3.5 ng/ml). The majority of psychomotor function parameters during the carbamazepine treatment were not significantly different from those during the placebo treatment, probably because of the sedative effect of carbamazepine itself. The present study suggests that carbamazepine decreases plasma concentration of alprazolam by inducing its metabolism. It also supports the previous studies, suggesting that alprazolam is metabolized predominantly by CYP3A4.

Keywords: Alprazolam; Carbamazepine; Single oral dose; Pharmacokinetics; Metabolism; CYP3A4
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
Full Text Full Text
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 1998 by the American College of Neuropsychopharmacology